CEO TarGlio (The Collider Programme)
TARGLIO | Nanoparticles for Glioblastoma Targeting & Magnetic Hyperthermia
CEO & Co-Founder Opportunity | DeepTech | Nanomedicine | Oncology
Are you ready to build a high-impact deep-tech spin-off addressing aggressive and lethal brain tumors?
TARGLIO is developing magnetic nanoparticles engineered to efficiently cross the blood–brain barrier (BBB) and enable targeted glioblastoma therapy through MRI-guided magnetic hyperthermia. The technology has been validated at TRL 4, including preliminary preclinical studies in glioblastoma models.
We are looking for an entrepreneurial CEO to lead the creation of the spin-off and drive regulatory, preclinical, fundraising and partnering strategy.
About TARGLIO
While nanomedicine has emerged as a promising field, most nanotherapeutics fail because they cannot efficiently cross the BBB and achieve effective tumor targeting. TARGLIO has developed iron-oxide magnetic nanoparticles (NPs) functionalized with a glucose derivative that leverages the overexpression of GLUT transporters in tumor vasculature.
Why TARGLIO
- Unique capacity to cross the tumor BBB after intravenous administration, overcoming the main bottleneck in brain cancer nanotherapies
- Technology validated as a medical device (MDx) in laboratory (TRL 4)
- Preliminary preclinical validation in glioblastoma models
- Strong theranostic positioning (diagnosis + therapy)
- Clear path toward TRL 7 preclinical completion and acquisition/licensing strategy
Your Role as CEO & Co-Founder (Next 6 Months)
You will lead TARGLIO through a decisive structuring phase:
- Spin-off creation and alignment with the Technology Transfer Office
- Definition of regulatory strategy (MD vs combination product considerations)
- Structuring preclinical roadmap toward TRL 7
- Fundraising strategy (public & private grants, early investors)
- Strategic positioning (acquisition vs sublicensing pathway)
- Identification of medtech or oncology partners
- Business model refinement (B2B partnering with medtech players)
Current Founding Team
- Carlos Caro
- Marisa García
- Manuel Pernía
The Offer
- Relevant equity as CEO & Co-Founder upon company incorporation
- €6,000 stipend during validation phase (3 monthly instalments of €2,000)
- Opportunity to access a participative loan of up to €50,000 to finance early-stage activities
- Access to The Collider venture-building programme, including: Regulatory, IP and clinical development mentors, DeepTech and healthcare industry experts, Support in spin-off creation and shareholder structuring.
- International exposure through The Collider ecosystem (4YFN, Mobile World Congress, corporate & investor networks)
- Coworking space in Barcelona (Tech Barcelona – Pier 01)
- Venture-builder support for two years post-incorporation, including in-kind services, community access and portfolio perks
This Opportunity Is for You If
- You are an entrepreneur with experience in biotech, medtech, nanomedicine or oncology innovation
- Previous founder/co-founder experience is highly valued
- Familiar with medical device regulation, combination products or translational nanomedicine
- Experience in fundraising and strategic partnerships
- Comfortable operating at the intersection of science, regulation and business
- Interested in acquisition-driven or sublicensing exit strategies
- Eligible to work in Spain
- Fluent in English and Spanish